Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lawrence Scott Blaszkowsky, M.D.

Co-Author

This page shows the publications co-authored by Lawrence Blaszkowsky and Dushyant Sahani.
Connection Strength

0.433
  1. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010 Jan; 11(1):48-54.
    View in: PubMed
    Score: 0.106
  2. Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX). J Clin Oncol. 2009 May 20; 27(15_suppl):4578.
    View in: PubMed
    Score: 0.102
  3. Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2020 07; 47(8):1871-1884.
    View in: PubMed
    Score: 0.053
  4. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013; 18(5):543-8.
    View in: PubMed
    Score: 0.034
  5. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013 Mar 15; 19(6):1557-66.
    View in: PubMed
    Score: 0.033
  6. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35.
    View in: PubMed
    Score: 0.026
  7. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study. J Clin Oncol. 2008 May 20; 26(15_suppl):4521.
    View in: PubMed
    Score: 0.024
  8. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9.
    View in: PubMed
    Score: 0.020
  9. A phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with hepatocellular carcinoma. J Clin Oncol. 2005 Jun; 23(16_suppl):4120.
    View in: PubMed
    Score: 0.019
  10. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.